PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells.
By Y. Latchman, Spencer C. Liang, Yin-Xia Wu, T. Chernova, R. Sobel, M. Klemm, V. Kuchroo, G. Freeman, Arlene H. Sharpe. Proceedings of the National Academy of Sciences of the United States of America, 2004
690 citations recorded by the source corpus.
Subfields: Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/2c4721e17a9093801022d1e82565f8d4bb4aabfa
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
- Arlene H. Sharpe
- G. Freeman
- Loise M. Francisco
- E. Buchbinder
- Anupam M. Desai
- P. Sage
- V. Kuchroo
- Razelle Kurzrock
In Oncology
- Arlene H. Sharpe
- G. Freeman
- Loise M. Francisco
- E. Buchbinder
- Anupam M. Desai
- P. Sage
- V. Kuchroo
- Razelle Kurzrock
Citations in the corpus
- Characterization of Hepatitis B Virus (HBV)-Specific T-Cell Dysfunction in Chronic HBV Infection (2007, background): “Recent studies indicate that exhausted T cells chronically exposed to high antigen loads express PD-1 (8, 14, 19, 23) and that the blocking of PD-1/PD-L1 engagement allows for the recovery of T-cell functions (1, 7, 23, 30, 32).”
- CTLA-4 and PD-1 Pathways (2016, background): “The B7 ligands for CTLA-4 are expressed by professional APCs, which typically reside in lymph nodes or spleen(2); however, PD-L1 and PD-L2 are more widely expressed.(2,10,23,24) PD-L1 is expressed on leukocytes, on nonhematopoietic cells, and in nonlymphoid tissues, and can be induced on parenchymal”
- The PD-1 Pathway in Tolerance and Autoimmunity (2010, background): “PD-L2, are predominantly responsible for regulating disease severity (173, 174).”
- PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity (2017, methodology): “Pdcd1−/−, Cd274−/−, and Pdcd1lg2−/− mice on the C57BL/6 background were generated in the Sharpe laboratory (Latchman et al., 2004; Keir et al., 2006, 2007).”
- PD-1 and its ligands in tolerance and immunity. (2008, background): “There are limited studies of PD-L1 function on T cells, but studies of PD-L1−/− T cells indicate that PD-L1 on T cells can downregulate T cell cytokine production (53).”
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy (2015, background): “PD-L1 itself is expressed at two potentially clinically relevant immunologic synapses—the tumor/T-cell interface, aswell as the APC/T-cell interface (62).”
- PD-1 Expression in Acute Hepatitis C Virus (HCV) Infection Is Associated with HCV-Specific CD8 Exhaustion (2006, background): “Many recent studies indicate that the PD-1/PD-1 ligand (PD-L1) pathway can play a role in T-cell exhaustion occurring when T cells are chronically exposed to high antigen loads and that blockade of PD-1/PDL-1 interaction can allow restoration of exhausted CD8 cells (1, 3, 4, 10, 12).”
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells (2009, background): “PD-L1/PD-L2/ (Keir et al., 2006) and PD-L1/ (Latchman et al., 2004) mice were generated in our laboratory.”
- Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. (2006, background): “www.aacrjournals.org 3383 Cancer Res 2006; 66: ( 7 ).”
- PD-L1 expression in human cancers and its association with clinical outcomes (2016, neutral): “tumor–immune interface may lead to a bias in PD-L1’s predictive value in cancers.(53) Furthermore, interferon-γ secreted”